Alkermes plc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 8AK.F | NBIX | 4119.TW | AMRX | AMLX | ALVO | |
|---|---|---|---|---|---|---|
| Market cap | 6.64B | 16.81B | 6.05B | 6.95B | 3.69B | 1.67B |
| P/E (TTM) | — | 24.6 | 99.2 | 49.9 | — | — |
| Forward P/E | 31.1 | 13.9 | 9.0 | 16.4 | -27.0 | 20.3 |
| Price/book | 4.0 | 4.3 | 1.1 | 12.6 | 13.7 | -8.7 |
| Dividend yield | — | — | 1.47% | — | — | — |
| 1-year change | +60.08% | +7.27% | −10.70% | +71.10% | +135.96% | −7.71% |
| Today | −1.99% | +0.73% | −0.59% | −1.29% | +0.68% | +2.86% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 20 min.
Latest news
All 8AK.F news ›Head to Head Contrast: Opus Genetics (NASDAQ:IRD) versus Alkermes (NASDAQ:ALKS)
Posted by Mitch Edgeman on Oct 31st, 2026 Opus Genetics (NASDAQ:IRD – Get Free Report) and Alkermes (NASDAQ:ALKS – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based…
Alkermes Q3 Preview: The Pipeline Looks Strong, But Earnings Tell Another Story
Alkermes is rated Buy as LUMRYZ momentum, LYBALVI trends, and pipeline progress drive growth despite near-term profit pressure. Click for more on ALKS stock. - Alkermes is maintained at a 'Buy' with a $57 price target, driven by LUMRYZ’s…
Alkermes to Report Third Quarter Financial Results on November 3, 2026
BioSpace Alkermes to Report Third Quarter Financial Results on November 3, 2026 DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
— ALKS 7290 is the First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful Improvements in ADHD Symptoms in Adults — — ALKS 7290 Was Generally Well Tolerated at All Doses Tested in Healthy Volunteers and Adults With ADHD — —…
Financial Survey: INmune Bio (NASDAQ:INMB) vs. Alkermes (NASDAQ:ALKS)
Posted by Mitch Edgeman on Oct 20th, 2026 Alkermes (NASDAQ:ALKS – Get Free Report) and INmune Bio (NASDAQ:INMB – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses…
Alkermes plc $ALKS Shares Sold by State of Alaska Department of Revenue
Posted by Defense World Staff on Oct 20th, 2026 Check Out Our Latest Stock Analysis on ALKS Founded in 1987, Alkermes is incorporated in Ireland and maintains its corporate headquarters in Waltham, Massachusetts. Avient Corporation $AVNT…
Truist Securities Reinstates Alkermes (ALKS) Coverage with Buy Rating and $55 Price Target
On October 16, 2026, Truist Securities resumed coverage of Alkermes PLC (NASDAQ: ALKS) with a Buy rating and set a price target of $55 per share. The firm emphasized the promising clinical profile of alixorexton, Alkermes' lead drug…
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research
— Data From Vibrance-1 Phase 2 Study Lancet Neurology Publication Evaluating Alixorexton in Narcolepsy Type 1 and Additional Data From Long-Term Extension Study in Narcolepsy Type 1 and Type 2 to be Shared in Oral Presentation — — Detailed…
Substance Use Disorder Treatment Market to Led by Indivior, Alkermes Camurus and Orexo | SNS Insider
openPR.com Substance Use Disorder Treatment Market to Led by Indivior, Alkermes Camurus and Orexo | SNS Insider Press release from: SNS Insider Pvt Ltd Substance Use Disorder Treatment Market Share
Analysts Are Bullish on These Healthcare Stocks: Alkermes (ALKS), MoonLake Immunotherapeutics (MLTX)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alkermes (ALKS), MoonLake Immunotherapeutics (MLTX) and Maze Therapeutics, Inc. (MAZE) with bullish sentiments. In a report released today, Paul…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com2
- biospace.com1
- defenseworld.net1
- gurufocus.com1
- markets.businessinsider.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.